3 10 48 https://ciencia.lugoneseditorial.com.ar/files/original/eef525ada63d083672c355c87d5f9a98.pdf 7877cc63b77ec708418ed0f4b191410e Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-eficacia-seguridad/">https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-eficacia-seguridad/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Eficacia, seguridad y satisfacción con el uso de Hyaluromax Skin Builder L® Subject The topic of the resource Estudio que confirma la eficacia, seguridad y satisfacción con el uso de complejos híbridos de ácido hialurónico de 1800 kDa con AH de 2500 kDa Description An account of the resource Estudio que confirma la eficacia, seguridad y satisfacción con el uso de complejos híbridos de ácido hialurónico de 1800 kDa con AH de 2500 kDa Creator An entity primarily responsible for making the resource Dra. Ana Karina Sanz, Médica Cirujana, MS Centro Médico de Estética Avanzada, Región Metropolitana, Buin, Chile Source A related resource from which the described resource is derived I. Kim BJ, Choi JH, Lee Y. Development of facial rejuvenation procedures. Thirty years of clinical experience with face lifts. Arch Plast Surg 2015 Sep;42(5):521-31. doi: 10.5999/ aps.2015.42.5.521. II. Alves R, Castro-Esteves T, Trelles MA. Intrinsec and extrinsec factors related to cutaneous aging. Cir Plast Iberol 2013;39(1):89-102. III. Ruiz-Martínez MA, Morales-Hernández MA. Approach to the treatment of skin aging. Ars Pharm 2025;56(4). IV. Kerscher M, Bayrhammer J, Reuther T. Rejuvenating influence of a stabilized hyaluronic acid-based gel of nonanimal origin on facial skin aging. Dermatol Surg 2008 May;34(5):720-6. doi: 10.1111/j.1524-4725.2008.34176.x. V. Wang F, Garza LA, Kang S, Varani J, Orringer JS, Fisher GJ, Voorhees JJ. In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin. Arch Dermatol 2007 Feb;143(2):155-63. doi: 10.1001/ archderm.143.2.155. VI. Goltsova E, Shemonaeva O. Hybrid cooperative complexes of H-HA and L-HA (Profhilo®) and the BAP technique for facial skin bioremodeling: a clinical experience at the NEO-Clinic (Tyumen, Russia). Esperienze Dermatologiche 2019;21:47-53. VII. Trévidic P, Kaufman-Janette J, Weinkle S, Wu R, Dhillon B, Antunes S, Macé E, Maffert P. Injection guidelines for treating midface volume deficiency with hyaluronic acid fillers. The ATP Approach (Anatomy, Techniques, Products). Aesthet Surg J 2022 Aug 1;42(8):920-934. doi: 10.1093/asj/sjac007. VIII. Maytin EV. Hyaluronan: more than just a wrinkle filler. Glycobiology 2016;26(6):553-559. doi: 10.1093/glycob/ cww033. IX. www.futerman.com.ar/hyaluromax. X. Administración Nacional de Medicamentos, Alimentos y Tecnología Médica. Instrucciones de uso de Hyaluromax Skin Builder L autorizadas por ANMAT. Disponible en:https://helena.anmat.gob.ar/Boletin/. XI. Cassuto D, Bellia G, Schiraldi C. An overview of soft tissue fillers for cosmetic dermatology: from filling to regenerative medicine. Clin Cosmet Investig Dermatol 2021 22;14:1857-1866. doi: 10.2147/CCID.S276676. XII. Enhance Me. Training Academy. Técnica BAP 8. Disponible en: https://www.enhance-me-training.com/ lessons/the-bap-technique/#:~:text=The%20BAP%20 technique%20(bio%20aesthetic%20points)&text=It%20 is%20injected%20in%20the,and%20improvement%20 of%20skin%20turgor. XIII. Vera RV, Morales SMA, Santa CFJ, et al. Escalas clínicas para evaluar el envejecimiento cutáneo: una revisión de la literatura. Rev Cent Dermatol Pascua 2021;30(2):68- 75. doi:10.35366/101176 Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editora de Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 11/12/2024 Contributor An entity responsible for making contributions to the resource Futerman Language A language of the resource Español Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.47196/0587">https://doi.org/10.47196/0587</a> 1800 kDa ácido hialurónico AH de 2500 kDa Ana Karina Sanz eficacia envejecimiento de la piel Futerman 2 Lidocaína Marcelo Robles seguridad Técnica BAP https://ciencia.lugoneseditorial.com.ar/files/original/294a8b80a8bccdf3118a4643728e34c6.pdf 7877cc63b77ec708418ed0f4b191410e Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-eficacia-seguridad/">https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-eficacia-seguridad/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Efficacy, safety and satisfaction with the use of Hyaluromax Skin Builder L® Subject The topic of the resource Study confirming the efficacy, safety and satisfaction with the use of hybrid complexes of 1800 kDa hyaluronic acid with 2500 kDa HA Description An account of the resource Study confirming the efficacy, safety and satisfaction with the use of hybrid complexes of 1800 kDa hyaluronic acid with 2500 kDa HA Creator An entity primarily responsible for making the resource Dr. Ana Karina Sanz, Surgeon, MS Medical Center for Advanced Aesthetics, Metropolitan Region, Buin, Chile Source A related resource from which the described resource is derived I. Kim BJ, Choi JH, Lee Y. Development of facial rejuvenation procedures. Thirty years of clinical experience with face lifts. Arch Plast Surg 2015 Sep;42(5):521-31. doi: 10.5999/ aps.2015.42.5.521. II. Alves R, Castro-Esteves T, Trelles MA. Intrinsec and extrinsec factors related to cutaneous aging. Cir Plast Iberol 2013;39(1):89-102. III. Ruiz-Martínez MA, Morales-Hernández MA. Approach to the treatment of skin aging. Ars Pharm 2025;56(4). IV. Kerscher M, Bayrhammer J, Reuther T. Rejuvenating influence of a stabilized hyaluronic acid-based gel of nonanimal origin on facial skin aging. Dermatol Surg 2008 May;34(5):720-6. doi: 10.1111/j.1524-4725.2008.34176.x. V. Wang F, Garza LA, Kang S, Varani J, Orringer JS, Fisher GJ, Voorhees JJ. In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin. Arch Dermatol 2007 Feb;143(2):155-63. doi: 10.1001/ archderm.143.2.155. VI. Goltsova E, Shemonaeva O. Hybrid cooperative complexes of H-HA and L-HA (Profhilo®) and the BAP technique for facial skin bioremodeling: a clinical experience at the NEO-Clinic (Tyumen, Russia). Esperienze Dermatologiche 2019;21:47-53. VII. Trévidic P, Kaufman-Janette J, Weinkle S, Wu R, Dhillon B, Antunes S, Macé E, Maffert P. Injection guidelines for treating midface volume deficiency with hyaluronic acid fillers. The ATP Approach (Anatomy, Techniques, Products). Aesthet Surg J 2022 Aug 1;42(8):920-934. doi: 10.1093/asj/sjac007. VIII. Maytin EV. Hyaluronan: more than just a wrinkle filler. Glycobiology 2016;26(6):553-559. doi: 10.1093/glycob/ cww033. IX. www.futerman.com.ar/hyaluromax. X. Administración Nacional de Medicamentos, Alimentos y Tecnología Médica. Instrucciones de uso de Hyaluromax Skin Builder L autorizadas por ANMAT. Disponible en:https://helena.anmat.gob.ar/Boletin/. XI. Cassuto D, Bellia G, Schiraldi C. An overview of soft tissue fillers for cosmetic dermatology: from filling to regenerative medicine. Clin Cosmet Investig Dermatol 2021 22;14:1857-1866. doi: 10.2147/CCID.S276676. XII. Enhance Me. Training Academy. Técnica BAP 8. Disponible en: https://www.enhance-me-training.com/ lessons/the-bap-technique/#:~:text=The%20BAP%20 technique%20(bio%20aesthetic%20points)&amp;text=It%20 is%20injected%20in%20the,and%20improvement%20 of%20skin%20turgor. XIII. Vera RV, Morales SMA, Santa CFJ, et al. Escalas clínicas para evaluar el envejecimiento cutáneo: una revisión de la literatura. Rev Cent Dermatol Pascua 2021;30(2):68- 75. doi:10.35366/101176 Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editor of Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 11 of december, 2024 Contributor An entity responsible for making contributions to the resource Futerman Language A language of the resource English Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.47196/0587">https://doi.org/10.47196/0587</a> 1800 kDa 2500 kDa HA Ana Karina Sanz BAP Technique efficacy Futerman 2 hyaluronic acid Lidocaine Marcelo Robles safety skin aging Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/terapia-oral-psoriasis-deucravacitinib/">https://lugoneseditorial.com.ar/novedades/dermatologia/terapia-oral-psoriasis-deucravacitinib/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Terapia oral innovadora para la psoriasis Description An account of the resource Con una alta eficacia y un perfil de seguridad favorable, deucravacitinib resulta una terapia oral innovadora para la psoriasis en placas de moderada a severa. Su vía oral es una gran ventaja y promete mejorar significativamente el manejo de la enfermedad. Creator An entity primarily responsible for making the resource Claudio Greco, Médico Dermatólogo, Miembro del Grupo de Psoriasis y Vitiligo de la Sociedad Argentina de Dermatología, Coordinador del Grupo de Hidradenitis Supurativa Source A related resource from which the described resource is derived I. Warren RB, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in plaque psoriasis. Psoriasis Area and Severity Index (PASI) outcomes over 4 years in patients receiving continuous deucravacitinib in the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at the 33rd European Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. II. Warren RB, et al. Deucravacitinib in plaque psoriasis. 4-year efficacy results by prior biologic treatment in the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at the 33rd European Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. III. Thaçi D, et al. Deucravacitinib efficacy in patients with moderate to severe psoriasis with scalp and fingernail disease. Response over 4 years of treatment in the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at the 33rdEuropean Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. IV. Thaçi D, et al. Deucravacitinib efficacy in Psoriasis Area and Severity Index (PASI) target outcomes through 4 years in the phase 3 POETYK trials in moderate to severe plaque psoriasis Presented at the 33rd European Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. V. Gooderham MJ, Hong CH, Litvinov IV. Selective TYK2 inhibition in the treatment of moderate to severe chronic plaque psoriasis. Skin Therapy Letter 2022;27(6). VI. Armstrong AW, Warren RB, Zhong Y, et al. Short-, mid-, and long-term efficacy of deucravacitinib versus biologics and nonbiologics for plaque psoriasis. A network meta-analysis. Dermatology and Therapy. 2023 Nov;13(11):2839-2857. Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editora de Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 13/12/2024 Contributor An entity responsible for making contributions to the resource Bristol Myers Language A language of the resource Español Bristol Claudio Greco Deucravacitinib eficacia Perfil de seguridad Psoriasis Psoriasis en placa Terapia oral Infección por dengue en diabetes Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/terapia-oral-psoriasis-deucravacitinib/">https://lugoneseditorial.com.ar/novedades/dermatologia/terapia-oral-psoriasis-deucravacitinib/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Innovative oral therapy for psoriasis Description An account of the resource With high efficacy and a favorable safety profile, deucravacitinib is an innovative oral therapy for moderate to severe plaque psoriasis. Its oral route is a great advantage and promises to significantly improve the management of the disease. Creator An entity primarily responsible for making the resource Dr. Claudio Greco, Dermatologist, Member of the Psoriasis and Vitiligo Group of the Argentine Society of Dermatology, Coordinator of the Hidradenitis Suppurativa Group Source A related resource from which the described resource is derived I. Warren RB, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in plaque psoriasis. Psoriasis Area and Severity Index (PASI) outcomes over 4 years in patients receiving continuous deucravacitinib in the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at the 33rd European Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. II. Warren RB, et al. Deucravacitinib in plaque psoriasis. 4-year efficacy results by prior biologic treatment in the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at the 33rd European Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. III. Thaçi D, et al. Deucravacitinib efficacy in patients with moderate to severe psoriasis with scalp and fingernail disease. Response over 4 years of treatment in the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at the 33rdEuropean Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. IV. Thaçi D, et al. Deucravacitinib efficacy in Psoriasis Area and Severity Index (PASI) target outcomes through 4 years in the phase 3 POETYK trials in moderate to severe plaque psoriasis Presented at the 33rd European Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. V. Gooderham MJ, Hong CH, Litvinov IV. Selective TYK2 inhibition in the treatment of moderate to severe chronic plaque psoriasis. Skin Therapy Letter 2022;27(6). VI. Armstrong AW, Warren RB, Zhong Y, et al. Short-, mid-, and long-term efficacy of deucravacitinib versus biologics and nonbiologics for plaque psoriasis. A network meta-analysis. Dermatology and Therapy. 2023 Nov;13(11):2839-2857. Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editor of Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource December 13th, 2024 Contributor An entity responsible for making contributions to the resource Bristol Language A language of the resource English Bristol Claudio Greco Deucravacitinib efficacy Oral therapy Dengue infection in diabetes Plaque psoriasis Psoriasis Safety profile Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/diabetes/monitoreo-continuo-de-glucosa/">https://lugoneseditorial.com.ar/novedades/diabetes/monitoreo-continuo-de-glucosa/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Monitoreo continuo de glucosa: nuevo portal de diabetes Description An account of the resource En el nuevo Portal Abbott Diabetes destacados especialistas dictan cursos certificados y on demand sobre los últimos avances en monitoreo continuo de glucosa y tecnología aplicada a la diabetes. Exclusivo para profesionales de la salud. Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editora de Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 16 diciembre, 2024 Contributor An entity responsible for making contributions to the resource Abbott Diabetes Adrián Proietti Alejandro Dain Aspectos clave del uso del monitoreo continuo de glucosa Cursos certificados Cursos on demand Diabetes Florencia Siufi FreeStyle Libre Gabriela Rovira Laura Kabakian LibreView María Ruiz monitoreo continuo de glucosa Portal Abbott Diabetes Portal médico Tecnología aplicada a la diabetes Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/diabetes/monitoreo-continuo-de-glucosa/">https://lugoneseditorial.com.ar/novedades/diabetes/monitoreo-continuo-de-glucosa/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Continuous glucose monitoring: new diabetes portal Description An account of the resource In the new Abbott Diabetes Portal, leading specialists teach certified and on-demand courses on the latest advances in continuous glucose monitoring and technology applied to diabetes. Exclusively for health professionals. Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editor of Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource December 16, 2024 Contributor An entity responsible for making contributions to the resource Abbott Diabetes Abbott Diabetes Portal Adrián Proietti Alejandro Dain Certified courses continuous glucose monitoring Diabetes Florencia Siufi FreeStyle Libre Gabriela Rovira Key aspects of using continuous glucose monitoring Laura Kabakian LibreView María Ruiz Medical portal On-demand courses Technology applied to diabetes Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-nasolabiales/">https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-nasolabiales/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Evaluación de la eficacia y seguridad del ácido hialurónico reticulado 30 mg/ml para relleno de surcos nasolabiales Description An account of the resource Introducción: los surcos nasolabiales (SNL) son una región del rostro con gran movilidad que, durante el envejecimiento, están sometidos a cambios multifactoriales. Cientific Hyaluronic Facial Implant 30® es un relleno de ácido hialurónico reticulado (AHR) de 30 mg/ml desarrollado con el objetivo de optimizar los resultados de esta área facial tan dinámica. Objetivos: evaluar la seguridad y eficacia de Cientific Hyaluronic Facial Implant 30® (CH30), compuesto por AHR 30 mg/ml, para la corrección de SNL de moderados a severos. Materiales y métodos: estudio clínico multicéntrico, prospectivo, de 12 meses de duración, que incluyó 64 pacientes hombres y mujeres de entre 30 y 75 años con SNL de moderados a graves tratados en ambos SNL con CH30 para equilibrar la asimetría hasta lograr una corrección óptima. Las valoraciones de la eficacia por parte de evaluadores incluyeron el análisis de la gravedad de los SNL utilizando la Wrinkle Severity Rating Scale (WSRS) y la mejora con la Global Aesthetic Improvement Scale (GAIS). La seguridad se registró durante todo el estudio en función de los controles en cada cita y la comunicación de los eventos adversos por parte de los pacientes. Resultados: durante los 12 meses de seguimiento no se observaron eventos adversos. En el 100% de los casos, la corrección del defecto, la duración y la satisfacción fueron calificadas por los pacientes y los médicos con puntuaciones de “mejoradas” a “muy mejoradas”, observándose una disminución del efecto muy lento a los 12 meses. Conclusiones: el uso del AHR para el tratamiento de los SNL es una de las opciones más efectivas y seguras en la medicina estética actual. Su capacidad para restaurar el volumen, suavizar las arrugas y mejorar la calidad de la piel lo convierten en una herramienta clave para el rejuvenecimiento facial. La durabilidad de sus resultados, combinada con su baja tasa de complicaciones, hace que el AHR sea ampliamente recomendado para los pacientes que buscan una mejora estética natural y de larga duración, convirtiéndose en una de las intervenciones más populares en la medicina estética moderna. Creator An entity primarily responsible for making the resource Claudio Dachevsky: Médico Cirujano Plástico, Director General, Clínica Lipo Cirugía Plástica, San Pablo, Brasil Source A related resource from which the described resource is derived I. Russell-Goldman E, Murphy GF. The pathobiology of skin aging. New insights into an old dilemma. Am J Pathol 2020 Jul;190(7):1356-1369. doi: 10.1016/j. ajpath.2020.03.007. II. Lupo M. Hyaluronic acid fillers in facial rejuvenation. Seminars in cutaneous medicine and surgery 2006; 25:122-6. doi: 10.1016/j.sder.2006.06.011. III. Duranti F, Salti G, Bovani B, Calandra M, Rosati ML. Injectable hyaluronic acid gel for soft tissue augmentation. A clinical and histological study. Dermatol Surg 1998 Dec;24(12):1317-25. doi: 10.1111/j.1524-4725.1998.tb00007.x. IV. Braccini F, Fanian F, García P, et al Comparative clinical study for the efficacy and safety of two different hyaluronic acid-based fillers with Tri-Hyal versus Vycross technology. A long-term prospective randomized clinical trial. J Cosmet Dermatol 2023 Feb;22(2):473-485. doi: 10.1111/jocd.15200. V. Peña F. Factores relacionados a la durabilidad del ácido hialurónico reticulado. Rev Facultad de Medicina de la Universidad de lberoamérica 2023;2;13-21. doi 10.54376/rcmui.v2i2.148. VI. Wongprasert P, Dreiss CA, Murray G. Evaluating hyaluronic acid dermal fillers. A critique of current characterization methods. Dermatol Ther 2022 Jun;35(6):e15453. doi: 10.1111/dth.15453. VII. Sánchez-Carpintero D, Ruiz-Rodríguez R. Materiales de relleno: tipos, indicaciones y complicaciones. Actas Dermosifiliogr 2010;101(5):381-393. VIII. Bukhari SNA, Roswandi NL, Waqas M, Habib H, Hussain F, et al. Hyaluronic acid, a promising skin rejuvenating biomedicine. A review of recent updates and pre-clinical and clinical investigations on cosmetic and nutricosmetic effects. Int J Biol Macromol. 2018 Dec;120(Pt B):1682-1695. doi: 10.1016/j.ijbiomac.2018.09.188. IX. Martínez-Carpio PA, Vega López PM. Materiales de relleno temporales en medicina estética: revisión de la literatura sobre la incidencia de efectos adversos y complicaciones. Medicina Estética 2019;59(2):14-19. doi: 10.48158/MedicinaEstetica.059.02 X. Cifuentes-Mimoso T, Signes-Soler F. Estudio de efectos adversos tras tratamiento con implantes cutáneos de ácido hialurónico. Universitat Autonoma de Barcelona. Disponible en: https://semcc.com/master/files/Hialuronico%20y%20efectos%20adversos%20-%20Dras.%20Cifuentes%20y%20Signes.pdf. XI. Robles M. Estudio de seguridad y eficacia del ácido hialurónico reticulado en relleno de surcos nasolabiales. doi: 10.47196/0573. XII. Bogdan-Allemann I, Baumann L. Hyaluronic acid gel (Juvéderm) preparations in the treatment of facial wrinkles and folds. Clin Interv Aging 2008;3(4):629-34. Doi: 10.2147/cia.s3118. XIII. Jordan DR. Delayed inflammatory reaction to hyaluronic acid (Restylane). Ophthalmic Plast Reconstr Surg 2005 Sep;21(5):401-2. doi: 10.1097/01.iop.0000173194.18050.b8. XIV. NASHATM. The monograpf. Disponible en: https://es.scribd.com/document/507252742/Monograph-ofNASHA. XV. Cornejo P, Alcolea JM, Trelles MA. Perspectivas en el uso de materiales de relleno inyectables para tejidos blandos, desde nuestra experiencia. 1º parte. Cir Plast Iberolatinoam 2011;37(4):393-402. doi: 10.4321/S037678922011000400013. XVI. Day D, Littler C, Swift R, Gottlieb S. The Wrinkle Severity Scale. American Journal of Clinical Dermatology 2004;5:49-52. doi: 10.2165/00128071-200405010-00007. XVII. Dibernardo G, DiBernardo B. Prediction of treatment outcomes for neck rejuvenation Utilizing a unique classification system of treatment approach using a1440-nm side-firing laser. Aesthetic Surgery Journal 2018;38:S43-S51. doi: 10.1093/asj/sjy066. XVIII. Sundaram H, Shamban A, Schlessinger J, KaufmanJanette J, Joseph JH, Lupin M, Draelos Z, Carey W, Smith S, Eaton L. Efficacy and safety of a new resilient hyaluronic acid filler in the correction of moderateto-severe dynamic perioral rhytides. A 52-week prospective, multicenter, controlled, randomized, evaluator-blinded study. Dermatol Surg. 2022 Jan 1;48(1):87-93. doi: 10.1097/DSS.0000000000003238. XIX. Abduljabbar MH, Basendwh MA. Complications of hyaluronic acid fillers and their managements. Journal of Dermatology & Dermatologic Surgery 2016;20(2). doi: 10.1016/j.jdds.2016.01.001. XX. Instrucciones de uso del producto Cientific Hyaluronic Facial Implant 30. Disponible en: https://es.scribd. com/document/265233528/Cientific-Hyaluronic-FacialImplant-30y18. XXI. Kaufman-Janette J, Taylor SC, Cox SE, Weinkle SH, Smith S, Kinney BM. Efficacy and safety of a new resilient hyaluronic acid dermal filler, in the correction of moderate-to-severe nasolabial folds. A 64-week, prospective, multicenter, controlled, randomized, doubleblind and within-subject study. J Cosmet Dermatol 2019 Oct;18(5):1244-1253. doi: 10.1111/jocd.13100. XXII. Dayan S, Maas CS, Grimes PE, Beer K, Monheit G, Snow S, Murphy DK, Lin V. Safety and effectiveness of VYC17.5L for long-term correction of nasolabial folds. Aesthet Surg J 2020 Jun 15;40(7):767-777. doi: 10.1093/ asj/sjz200. Publisher An entity responsible for making the resource available Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 31/03/2025 Contributor An entity responsible for making contributions to the resource Allanmar International Company S.R.L Type The nature or genre of the resource DOI: <a href="https://doi.org/10.47196/0590">https://doi.org/10.47196/0590</a> ácido hialurónico ácido hialurónico reticulado Claudio Dachevsky eficacia Hyaluromax Marcelo Robles Rejuvenecimiento facial seguridad surcos nasolabiales https://ciencia.lugoneseditorial.com.ar/files/original/a99411b509f6b3485fb4c2272a46cd81.pdf 4c176201408ce815a005919d9835d6c2 Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-nasolabiales/">https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-nasolabiales/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Evaluation of the efficacy and safety of cross-linked hyaluronic acid 30 mg/ml for filling nasolabial folds Description An account of the resource Introduction: the nasolabial folds (NLF) are a highly mobile facial region that undergoes multifactorial changes during aging. Cientific Hyaluronic Facial Implant 30® is a 30 mg/ml cross-linked hyaluronic acid (HRA) filler developed to optimize the results of this highly dynamic facial area. Objectives: to evaluate the safety and efficacy of Cientific Hyaluronic Facial Implant 30® (CH30), composed of 30 mg/ml HRA, for the correction of moderate to severe NLF. Materials and methods: a 12-month, prospective, multicenter clinical study that included 64 male and female patients between 30 and 75 years of age with moderate to severe NLF treated in both NLFs with CH30 to balance the asymmetry until optimal correction was achieved. Efficacy assessments by evaluators included analysis of NLF severity using the Wrinkle Severity Rating Scale (WSRS) and improvement using the Global Aesthetic Improvement Scale (GAIS). Safety was recorded throughout the study based on checks at each appointment and patient reporting of adverse events. Results: no adverse events were observed during the 12-month follow-up. In 100% of cases, defect correction, duration, and satisfaction were rated by patients and physicians as “improved” to “very improved,” with a very slow decrease in effect observed at 12 months. Conclusions: the use of AHR for the treatment of NLF is one of the most effective and safe options in current aesthetic medicine. Its ability to restore volume, smooth wrinkles, and improve skin quality make it a key tool for facial rejuvenation. The durability of the results, combined with its low complication rate, makes HRA widely recommended for patients seeking a natural and longlasting aesthetic improvement, making it one of the most popular interventions in modern aesthetic medicine. Creator An entity primarily responsible for making the resource Claudio Dachevsky: Plastic Surgeon, General Manager, Lipo Plastic Surgery Clinic, São Paulo, Brazil Source A related resource from which the described resource is derived I. Russell-Goldman E, Murphy GF. The pathobiology of skin aging. New insights into an old dilemma. Am J Pathol 2020 Jul;190(7):1356-1369. doi: 10.1016/j. ajpath.2020.03.007. II. Lupo M. Hyaluronic acid fillers in facial rejuvenation. Seminars in cutaneous medicine and surgery 2006; 25:122-6. doi: 10.1016/j.sder.2006.06.011. III. Duranti F, Salti G, Bovani B, Calandra M, Rosati ML. Injectable hyaluronic acid gel for soft tissue augmentation. A clinical and histological study. Dermatol Surg 1998 Dec;24(12):1317-25. doi: 10.1111/ j.1524-4725.1998.tb00007.x. IV. Braccini F, Fanian F, García P, et al Comparative clinical study for the efficacy and safety of two different hyaluronic acid-based fillers with Tri-Hyal versus Vycross technology. A long-term prospective randomized clinical trial. J Cosmet Dermatol 2023. Feb;22(2):473-485. doi: 10.1111/jocd.15200. V. Peña F. Factores relacionados a la durabilidad del ácido hialurónico reticulado. Rev Facultad de Medicina de la Universidad de lberoamérica 2023;2;13-21. doi 10.54376/rcmui.v2i2.148. VI. Wongprasert P, Dreiss CA, Murray G. Evaluating hyaluronic acid dermal fillers. A critique of current characterization methods. Dermatol Ther 2022 Jun;35(6):e15453. doi: 10.1111/dth.15453. VII. Sánchez-Carpintero D, Ruiz-Rodríguez R. Materiales de relleno: tipos, indicaciones y complicaciones. Actas Dermosifiliogr 2010;101(5):381-393. VIII. Bukhari SNA, Roswandi NL, Waqas M, Habib H, Hussain F, et al. Hyaluronic acid, a promising skin rejuvenating biomedicine. A review of recent updates and pre-clinical and clinical investigations on cosmetic and nutricosmetic effects. Int J Biol Macromol. 2018 Dec;120(Pt B):1682-1695. doi: 10.1016/j. ijbiomac.2018.09.188. IX. Martínez-Carpio PA, Vega López PM. Materiales de relleno temporales en medicina estética: revisión de la literatura sobre la incidencia de efectos adversos y complicaciones. Medicina Estética 2019;59(2):14-19. doi: 10.48158/MedicinaEstetica.059.02 X. Cifuentes-Mimoso T, Signes-Soler F. Estudio de efectos adversos tras tratamiento con implantes cutáneos de ácido hialurónico. Universitat Autonoma de Barcelona. Disponible en: https://semcc.com/master/files/Hialuronico%20y%20efectos%20adversos%20-%20Dras.%20Cifuentes%20y%20Signes.pdf. XI. Robles M. Estudio de seguridad y eficacia del ácido hialurónico reticulado en relleno de surcos nasolabiales. doi: 10.47196/0573. XII. Bogdan-Allemann I, Baumann L. Hyaluronic acid gel (Juvéderm) preparations in the treatment of facial wrinkles and folds. Clin Interv Aging 2008;3(4):629-34. Doi: 10.2147/cia.s3118. XIII. Jordan DR. Delayed inflammatory reaction to hyaluronic acid (Restylane). Ophthalmic Plast Reconstr Surg 2005 Sep;21(5):401-2. doi: 10.1097/01.iop.0000173194.18050.b8. XIV. NASHATM. The monograpf. Disponible en: https://es.scribd.com/document/507252742/Monograph-ofNASHA. XV. Cornejo P, Alcolea JM, Trelles MA. Perspectivas en el uso de materiales de relleno inyectables para tejidos blandos, desde nuestra experiencia. 1º parte. Cir Plast Iberolatinoam 2011;37(4):393-402. doi: 10.4321/S037678922011000400013. XVI. Day D, Littler C, Swift R, Gottlieb S. The Wrinkle Severity Scale. American Journal of Clinical Dermatology 2004;5:49-52. doi: 10.2165/00128071-200405010-00007. XVII. Dibernardo G, DiBernardo B. Prediction of treatment outcomes for neck rejuvenation Utilizing a unique classification system of treatment approach using a 1440-nm side-firing laser. Aesthetic Surgery Journal 2018;38:S43-S51. doi:10.1093/asj/sjy066. Ther 2022 XVIII. Sundaram H, Shamban A, Schlessinger J, Kaufman. Janette J, Joseph, JH, Lupin M, Draelos Z, Carey W, Smith S, Eaton L. Efficacy and safety of a new resilient hyaluronic acid filler in the correction of moderateto-severe dynamic perioral rhytides. A 52-week prospective, multicenter, controlled, randomized, evaluator-blinded study. Dermatol Surg. 2022 Jan 1;48(1):87-93. doi: 10.1097/DSS.0000000000003238. XIX. Abduljabbar MH, Basendwh MA. Complications of hyaluronic acid fillers and their managements. Journal of Dermatology & Dermatologic Surgery 2016;20(2). doi: 10.1016/j.jdds.2016.01.001. XX. Instrucciones de uso del producto Cientific Hyaluronic Facial Implant 30. Disponible en: https://es.scribd.com/document/265233528/Cientific-Hyaluronic-FacialImplant-30y18. XXI. Kaufman-Janette J, Taylor SC, Cox SE, Weinkle SH, Smith S, Kinney BM. Efficacy and safety of a new resilient hyaluronic acid dermal filler, in the correction of moderate-to-severe nasolabial folds. A 64-week, prospective, multicenter, controlled, randomized, doubleblind and within-subject study. J Cosmet Dermatol 2019 Oct;18(5):1244-1253. doi: 10.1111/jocd.13100. XXII. Dayan S, Maas CS, Grimes PE, Beer K, Monheit G, Snow S, Murphy DK, Lin V. Safety and effectiveness of VYC17.5L for long-term correction of nasolabial folds. Aesthet Surg J 2020 Jun 15;40(7):767-777. doi: 10.1093/asj/sjz200. Publisher An entity responsible for making the resource available Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 31/03/2025 Contributor An entity responsible for making contributions to the resource Allanmar International Company S.R.L Identifier An unambiguous reference to the resource within a given context DOI: https://doi.org/10.47196/0590 Claudio Dachevsky Cross-linked hyaluronic acid Effectiveness Facial rejuvenation Hyaluromax hyaluronic acid Marcelo Robles nasolabial folds safety https://ciencia.lugoneseditorial.com.ar/files/original/2a6c6ecb1c66dcf339c3ba8ccd8b4e46.pdf 8364899a7975703c3ef38e7d8a210c6e Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/diabetes/monitoreo-continuo-de-glucosa-1/">https://lugoneseditorial.com.ar/novedades/diabetes/monitoreo-continuo-de-glucosa-1/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource ¿Por qué no todos los sistemas de monitoreo continuo de glucosa (MCG) son iguales? Description An account of the resource La FDA ha desarrollado una clasificación para los sistemas MCG que los divide en aquellos que requieren (complementarios) o no (no complementarios) del uso de tiras reactivas para la toma de decisiones seguras. Source A related resource from which the described resource is derived 1. Campbell F. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatric Diabetes 2018; 19(7):1294-1301. doi: 10.1111/pedi.12735. Publisher An entity responsible for making the resource available María Fernanda Cristoforetti Date A point or period of time associated with an event in the lifecycle of the resource 14/03/2025 Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.47196/0592">https://doi.org/10.47196/0592</a> Abbott Diabetes Clasificación MCG Diabetes MCG MCG complementario MCG no complementario monitoreo continuo de glucosa Ventajas MCG no complementarios https://ciencia.lugoneseditorial.com.ar/files/original/6b557998973ef330a313d5a6bf13e325.pdf 8364899a7975703c3ef38e7d8a210c6e Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/diabetes/monitoreo-continuo-de-glucosa-1/">https://lugoneseditorial.com.ar/novedades/diabetes/monitoreo-continuo-de-glucosa-1/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Why aren't all continuous glucose monitoring (CGM) systems the same? Description An account of the resource The FDA has developed a classification for CGM systems that divides them into those that require (complementary) or do not (non-complementary) the use of test strips for safe decision making. Source A related resource from which the described resource is derived 1. Campbell F. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatric Diabetes 2018; 19(7):1294-1301. doi: 10.1111/pedi.12735. Publisher An entity responsible for making the resource available María Fernanda Cristoforetti Date A point or period of time associated with an event in the lifecycle of the resource 14/03/2025 Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.47196/0592">https://doi.org/10.47196/0592</a> Abbott Diabetes Advantages of Non-complementary CGM CGM CGM Classification Complementary CGM continuous glucose monitoring Diabetes Non-complementary CGM